Seattle Genetics, Inc. (NASDAQ:SGEN) Files An 8-K Other Events

0

Seattle Genetics, Inc. (NASDAQ:SGEN) Files An 8-K Other Events
Item 8.01 Other Events.

On March 9, 2017, the Delaware Court of Chancery issued a temporary restraining order enjoining taking any action in furtherance of the closing of the development and license agreement between Seattle Genetics, Inc. and Immunomedics, Inc. regarding sacituzumab govitecan (IMMU-132). The temporary restraining order will remain in place pending a hearing on an application for preliminary injunction to be held in approximately thirty days.


About Seattle Genetics, Inc. (NASDAQ:SGEN)

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company’s product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC), comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). The Company’s pipeline includes other clinical-stage ADC programs, which are SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. SGN-CD33A is an ADC composed of an anti-CD33 monoclonal antibody indicated for the treatment of acute myeloid leukemia (AML). SGN-CD19A is an ADC composed of an anti-CD19 monoclonal antibody indicated for the treatment of hematologic malignancies. SGN-LIV1A is an ADC composed of an anti-LIV-1 monoclonal antibody indicated for the treatment of LIV-1-positive metastatic breast cancer.

Seattle Genetics, Inc. (NASDAQ:SGEN) Recent Trading Information

Seattle Genetics, Inc. (NASDAQ:SGEN) closed its last trading session down -0.33 at 67.10 with 1,181,140 shares trading hands.